ZA200206119B - Use of pramipexole for the treatment of addictive disorders. - Google Patents
Use of pramipexole for the treatment of addictive disorders. Download PDFInfo
- Publication number
- ZA200206119B ZA200206119B ZA200206119A ZA200206119A ZA200206119B ZA 200206119 B ZA200206119 B ZA 200206119B ZA 200206119 A ZA200206119 A ZA 200206119A ZA 200206119 A ZA200206119 A ZA 200206119A ZA 200206119 B ZA200206119 B ZA 200206119B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- disorders
- composition
- treatment
- day
- Prior art date
Links
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims description 38
- 229960003089 pramipexole Drugs 0.000 title claims description 37
- 238000011282 treatment Methods 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 241000208125 Nicotiana Species 0.000 claims description 23
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 206010012335 Dependence Diseases 0.000 claims description 16
- 206010057852 Nicotine dependence Diseases 0.000 claims description 16
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000011117 substance-related disease Diseases 0.000 claims description 10
- 230000035987 intoxication Effects 0.000 claims description 9
- 231100000566 intoxication Toxicity 0.000 claims description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- 229960002715 nicotine Drugs 0.000 claims description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
- 230000000391 smoking effect Effects 0.000 claims description 8
- 230000001055 chewing effect Effects 0.000 claims description 7
- 208000007848 Alcoholism Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 235000019788 craving Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 21
- 230000002708 enhancing effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000036765 blood level Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 4
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- KWFASKPXXSVNIQ-UHFFFAOYSA-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,4-diamine Chemical compound C1C(CCC)CC(N)C2=C1SC(N)=N2 KWFASKPXXSVNIQ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- QMNWXHSYPXQFSK-UHFFFAOYSA-N hydron;6-n-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dichloride Chemical compound Cl.Cl.C1C(NCCC)CCC2=C1SC(N)=N2 QMNWXHSYPXQFSK-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940124708 psychiatric therapeutics Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18424200P | 2000-02-23 | 2000-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206119B true ZA200206119B (en) | 2003-10-31 |
Family
ID=22676121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206119A ZA200206119B (en) | 2000-02-23 | 2002-07-31 | Use of pramipexole for the treatment of addictive disorders. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6410579B2 (de) |
| EP (1) | EP1257271B1 (de) |
| JP (1) | JP2003523387A (de) |
| KR (1) | KR20030016230A (de) |
| CN (1) | CN1396826A (de) |
| AR (1) | AR027945A1 (de) |
| AT (1) | ATE326967T1 (de) |
| AU (1) | AU781358B2 (de) |
| BR (1) | BR0107983A (de) |
| CA (1) | CA2397874A1 (de) |
| CO (1) | CO5261586A1 (de) |
| DE (1) | DE60119896T2 (de) |
| DK (1) | DK1257271T3 (de) |
| ES (1) | ES2263586T3 (de) |
| HK (1) | HK1053058A1 (de) |
| MX (1) | MXPA02008184A (de) |
| MY (1) | MY127739A (de) |
| NZ (1) | NZ520974A (de) |
| PE (1) | PE20011074A1 (de) |
| PT (1) | PT1257271E (de) |
| SI (1) | SI1257271T1 (de) |
| TW (1) | TWI250016B (de) |
| WO (1) | WO2001062249A1 (de) |
| ZA (1) | ZA200206119B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| EP2305252A1 (de) | 2001-12-11 | 2011-04-06 | University Of Virginia Patent Foundation | Verwendung von Pramipexol zur Behandlung amyotropher Lateralsklerose |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| MY142204A (en) * | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| CA2554616A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| MX2007001850A (es) * | 2004-08-13 | 2007-03-28 | Boehringer Ingelheim Int | Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo. |
| EP1781260B2 (de) * | 2004-08-13 | 2014-04-02 | Boehringer Ingelheim International GmbH | Tablettenformulierung mit verlängerter freisetzung enthaltend pramipexol oder ein pharmazeutisch annehmbares salz, die herstellungsmethode und die verwendung der tabletten |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| CA2652251A1 (en) | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions of r(+) and s(-) pramipexole and methods for using the same |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| ATE513830T1 (de) * | 2007-09-21 | 2011-07-15 | Sanofi Aventis | Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| DE102012108398B4 (de) | 2012-09-10 | 2014-05-22 | Schott Ag | Kochfeld, Blende, Geräteeinhausung sowie Kamin- oder Ofensichtscheibe mit einem Hologramm und Verfahren zu dessen bzw. deren Herstellung, sowie Verwendung eines Substrats, auf welchem ein Phasenhologramm aufgebracht ist |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
| ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| DE3843227A1 (de) | 1988-12-22 | 1990-07-05 | Boehringer Ingelheim Kg | Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol |
| DE3930282A1 (de) | 1989-09-11 | 1991-03-21 | Boehringer Ingelheim Kg | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit |
| DE3933738A1 (de) | 1989-10-10 | 1991-04-11 | Boehringer Ingelheim Kg | Neue verwendung von 2-aminothiazol-derivaten (tsh) |
| DE3937271A1 (de) | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| DE4241013A1 (de) | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| US5650420A (en) | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
| US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| CA2384840A1 (en) | 1999-09-30 | 2001-04-05 | The General Hospital Corporation | Use of pramipexole as a treatment for cocaine craving |
-
2001
- 2001-02-07 PE PE2001000131A patent/PE20011074A1/es not_active Application Discontinuation
- 2001-02-09 MY MYPI20010581A patent/MY127739A/en unknown
- 2001-02-14 SI SI200130592T patent/SI1257271T1/sl unknown
- 2001-02-14 JP JP2001561315A patent/JP2003523387A/ja active Pending
- 2001-02-14 ES ES01906557T patent/ES2263586T3/es not_active Expired - Lifetime
- 2001-02-14 DK DK01906557T patent/DK1257271T3/da active
- 2001-02-14 PT PT01906557T patent/PT1257271E/pt unknown
- 2001-02-14 CN CN01804037A patent/CN1396826A/zh active Pending
- 2001-02-14 NZ NZ520974A patent/NZ520974A/en unknown
- 2001-02-14 BR BR0107983-2A patent/BR0107983A/pt not_active Application Discontinuation
- 2001-02-14 EP EP01906557A patent/EP1257271B1/de not_active Revoked
- 2001-02-14 WO PCT/US2001/001232 patent/WO2001062249A1/en active IP Right Grant
- 2001-02-14 MX MXPA02008184A patent/MXPA02008184A/es active IP Right Grant
- 2001-02-14 AT AT01906557T patent/ATE326967T1/de not_active IP Right Cessation
- 2001-02-14 CA CA002397874A patent/CA2397874A1/en not_active Abandoned
- 2001-02-14 US US09/783,656 patent/US6410579B2/en not_active Expired - Fee Related
- 2001-02-14 KR KR1020027010951A patent/KR20030016230A/ko not_active Application Discontinuation
- 2001-02-14 AU AU34454/01A patent/AU781358B2/en not_active Ceased
- 2001-02-14 DE DE60119896T patent/DE60119896T2/de not_active Revoked
- 2001-02-20 AR ARP010100754A patent/AR027945A1/es unknown
- 2001-02-22 CO CO01014318A patent/CO5261586A1/es not_active Application Discontinuation
- 2001-02-23 TW TW090104177A patent/TWI250016B/zh not_active IP Right Cessation
-
2002
- 2002-07-31 ZA ZA200206119A patent/ZA200206119B/en unknown
-
2003
- 2003-07-24 HK HK03105334.1A patent/HK1053058A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY127739A (en) | 2006-12-29 |
| BR0107983A (pt) | 2003-01-28 |
| DK1257271T3 (da) | 2006-08-21 |
| AU3445401A (en) | 2001-09-03 |
| DE60119896D1 (de) | 2006-06-29 |
| AU781358B2 (en) | 2005-05-19 |
| HK1053058A1 (zh) | 2003-10-10 |
| PE20011074A1 (es) | 2001-10-04 |
| EP1257271A1 (de) | 2002-11-20 |
| US6410579B2 (en) | 2002-06-25 |
| ES2263586T3 (es) | 2006-12-16 |
| AR027945A1 (es) | 2003-04-16 |
| WO2001062249A1 (en) | 2001-08-30 |
| EP1257271B1 (de) | 2006-05-24 |
| ATE326967T1 (de) | 2006-06-15 |
| KR20030016230A (ko) | 2003-02-26 |
| US20010041727A1 (en) | 2001-11-15 |
| DE60119896T2 (de) | 2006-11-09 |
| CA2397874A1 (en) | 2001-08-30 |
| TWI250016B (en) | 2006-03-01 |
| CN1396826A (zh) | 2003-02-12 |
| CO5261586A1 (es) | 2003-03-31 |
| SI1257271T1 (sl) | 2006-10-31 |
| PT1257271E (pt) | 2006-09-29 |
| MXPA02008184A (es) | 2002-11-29 |
| NZ520974A (en) | 2004-04-30 |
| JP2003523387A (ja) | 2003-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU781358B2 (en) | Use of pramipexole for the treatment of addictive disorders | |
| US6194445B1 (en) | Use of pramipexole in the treatment of restless legs syndrome | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JP2009062388A (ja) | 不穏下肢症候群の治療におけるプラミペキソールの使用 | |
| US6841557B2 (en) | Compounds for the treatment of addictive disorders | |
| AU2001283393A1 (en) | Compounds for the treatment of addictive disorders | |
| EP1685838A1 (de) | Verbindungen zur Behandlung von Suchterkrankungen | |
| ZA200300220B (en) | Compounds for the treatment of addictive disorders. |